Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

OBJECTIVE: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between obje...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Liver Cancer
Autori principali: Kudo, Masatoshi, Ueshima, Kazuomi, Chiba, Yasutaka, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Arai, Yasuaki
Natura: Artigo
Lingua:Inglês
Pubblicazione: S. Karger AG 2019
Soggetti:
Original Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883462/
https://ncbi.nlm.nih.gov/pubmed/31799207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503032
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi